Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

But Sanofi isn’t only counting on Dupixent for growth. Vaccines are another key piece of the company’s strategy, and those products pulled in €1 billion for the quarter, a 16% increase.

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...

Sanofi expects Dupixent to achieve more than €13 billion in sales in 2024. For Regeneron, Dupixent generated collaboration revenues of $2.06 billion in the first half, up 18% year over year.

Dupixent has become the key driver of the top line for Sanofi and profits for Regeneron. Dupixent generated third-quarter global product sales of $1.66 billion, which were recorded by Sanofi.

Sanofi and Regeneron, which co-sell the drug, spent a massive $287.6 million on Dupixent ads last year, making them the highest of all pharma drug spenders in 2021.

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication. By Zacks Equity Research, Entrepreneur.comJan 21, 2022 ...